Allergy Therapeutics gains increased flexibility with FirstDoc upgrade

Client name: Allergy Therapeutics
Location: Worthing, UK
Industry: Life Sciences
Allergy Therapeutics gains increased flexibility with FirstDoc upgrade

UK-based Allergy Therapeutics is enjoying the benefits of a streamlined regulatory submission process following a cost-effective upgrade to the latest version of FirstDoc, DXC Technology’s life sciences regulatory information management solution. The specialty pharmaceutical company took advantage of DXC’s new approach to FirstDoc upgrades, which gives customers a wider range of options and a more straightforward, simpler upgrade path.

Allergy Therapeutics wanted to gain the benefits of a FirstDoc upgrade, and the project was delivered, as expected, on budget and on time. Now Allergy Therapeutics is positioned to recast this powerful technology to drive adoption by more users, gain better information sharing and benefit from improved overall content management.

A uniform system

As a leader in the development of innovative allergy vaccinations, it is essential for Allergy Therapeutics to have an up-to-date, efficient document management system to navigate the complex regulatory process.

“As a pharmaceutical company, we are a regulated environment, so we have to ensure that we have robust systems in place where people can access information and have good, tight security and ease of use,” says Pauline D’arcy, IT manager at Allergy Therapeutics.

Pauline says automation is another crucial requirement, and as the company expands its presence in the United States, having access to up-to-date regulatory information is more critical than ever. “Previously, no kind of tool existed in the regulatory environment to manage all of the documentation, so one of key advantages is that FirstDoc allows us to put that process into place,” she says.

Ken Herbert, regulatory affairs manager at Allergy Therapeutics, stresses the importance of having uniformity in a regulatory management system, which FirstDoc delivers. “Our entire function is the communication of facts about our company to our regulators, and we need to do that in an organized, controlled and secure fashion,” he says. When it comes to the FirstDoc upgrade, he says, “The new package is providing us with even more benefits than the previous version.”
A more flexible upgrade approach

As Allergy Therapeutics found, upgrading FirstDoc can be much simpler and less costly than it had been previously. DXC is employing a new, agile, cafeteria-style approach to FirstDoc upgrades that gives customers a wide range of upgrade options, varying in complexity and duration. If a light and nimble approach is preferred, DXC can deliver that.

“The upgrade went very, very smoothly,” says Pauline, citing flexibility as a key driver. “What we particularly liked was how we could pick and choose elements of the upgrade we wanted to do ourselves and what would be done by CSC (now DXC).” She says maintaining a strong level of management and control of the project helped Allergy Therapeutics cut down on upgrade costs.

Julie Gale, regulatory affairs systems coordinator at Allergy Therapeutics, says the upgrade was completed on schedule. “We did it all within the timeline that had been planned out,” she says. Also, Julie says that training provided by DXC has been helpful in getting additional functionality from FirstDoc, especially in the areas of permissions, document management and security.

From an IT infrastructure standpoint, Pauline says an important driver for undertaking the upgrade is that it provides up-to-date compatibility with newer versions of the Microsoft OS and the Internet Explorer browser. “We didn’t want to have our validation systems running on an OS that was no longer supported,” she says. In addition, the new version of FirstDoc decreases total cost of ownership by allowing for backward compatibility; an upgrade can save customers money because they will not have to support older software versions.
Improved end user access

The FirstDoc upgrade also improves ease of use. “Straightaway, the upgrade was a win-win situation for the end users,” Pauline says. “When they opened up FirstDoc, it was so much quicker. The speed with which they can access the information — there’s no comparison.”

This greater ease of use serves as an enticement for new users to come on board. Because more users mean higher-quality data, the wider reach of the product is making FirstDoc an even more powerful document management tool. Increased training has also introduced the full functionality of FirstDoc to expert users.

In addition, Julie says FirstDoc has helped streamline the regulatory submission process. “We can now generate and manage all of our regulatory submission documents in FirstDoc rather than some of the submissions being outside, and we are going to see a huge benefit from that,” she says. Now, with the upgrade complete, Allergy Therapeutics is positioned to tap into a more robust, streamlined regulatory information management solution.

Allergy Therapeutics is a pioneer in modern specific immunotherapy, a curative approach in allergic diseases. Like most pharma companies, getting products to market quickly is essential for the company to remain competitive. The upgrade to version 7 of FirstDoc is helping Allergy Therapeutics accelerate the regulatory process even more, by making it easier for the company to adjust procedures and filing practices. Ken says, “We can better align our different end users [with] their accessibility and different functions.”